Added to YB: 2026-09-21
Pitch date: 2026-09-17
145020.KQ [neutral]
Hugel, Inc.
-7.76%
current return
Author Info
Asian Century Stocks is a former buy-side investor in Asia that now focuses on researching value stocks in Asia and sharing them in his newsletter. Sign up for the newsletter.
Company Info
Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults aged between 18 and 65; treatment of upper limb stroke; and treatment of dynamic equinus foot deformity in children with cerebral palsy over 2 years of age, as well as improvement of external angles of secondary ideals related to orbicularis oculi muscle activity in adults aged between 19 and 65 under the Botulax, Regenox, Zentox, Reage, Magnion, Hugel Toxin, Juvenlife, Botulim, and Botoshot brands.
Market Cap
KRW 2.3T
Pitch Price
KRW 232.0K
Price Target
N/A
Dividend
N/A
EV/EBITDA
7.69
P/E
14.86
EV/Sales
3.68
Sector
Biotechnology
Category
growth
Insider activity August 2026 - Hugel, Inc.
145020.KQ (update): Hugel, Korea’s botulinum-toxin leader with 45% domestic share, trades at 16x trailing earnings as US entry lifted 2026 revenue growth above 20%, versus historical mid-teens growth. Its 47% 2025 operating margin shows the product economics, but front-loaded US investment, entrenched physician preferences and uncertain scale challenge targets of 10% US share by 2028 and 14% by 2030; the biggest question is whether largely undifferentiated toxins ultimately become commoditized.
Read full article (2 min)